{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:42:48Z","timestamp":1787726568877,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014605","name":"Sage Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Huntington\u2019s disease (HD) is a progressive neurodegenerative disease with a devastating impact on patients and their families. Quantifying how treatments affect patient outcomes is critical for informing reimbursement decisions. Many countries mandate a formal value assessment in which the treatment benefit is measured as quality-adjusted life-years, calculated with the use of utility estimates that reflect respondents\u2019 preferences for health states.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To summarize published health state utility data in HD and identify gaps and uncertainties in the data available that could be used to inform value assessments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a systematic literature review of studies that used preference-based instruments (e.g., EQ-5D and SF-6D) to estimate utility values for people with HD. The studies were published between January 2012 and December 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 383 articles screened, 16 articles reported utility values estimated in 11 distinct studies. The utility measure most frequently reported was EQ-5D (9\/11 studies). Two studies reported SF-6D data; one used time trade-off methods to value health state descriptions (vignettes). Although utility scores generally worsened to a lower value with increased HD severity, the estimates varied considerably across studies. The EQ-5D index range was 0.89\u2009\u2212\u20090.72 for mild\/prodromal HD and 0.71\u2009\u2212\u20090.37 for severe\/late-stage disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study uncovered high variability in published utility estimates, indicating substantial uncertainty in existing data. Further research is needed to better understand preferences and valuation across all stages and domains of HD symptoms and the degree to which generic utility measures capture the impact of cognitive changes on quality of life.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12955-024-02242-1","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:13:02Z","timestamp":1713280382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health state utility estimates for value assessments of novel treatments in Huntington\u2019s disease: a systematic literature review"],"prefix":"10.1186","volume":"22","author":[{"given":"Ruta","family":"Sawant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Paret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorrel","family":"Wolowacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ronquest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Rickards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"2242_CR1","unstructured":"Huntington\u2019s Together. About Huntington\u2019s disease. 2021. https:\/\/www.huntingtonsdiseasehcp.com\/about-huntingtons-disease.html"},{"key":"2242_CR2","doi-asserted-by":"crossref","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington\u2019s disease: an updated systematic review and meta-analysis. Mov Disord. 2022.","DOI":"10.1002\/mds.29228"},{"issue":"5","key":"2242_CR3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.12740\/PP\/34496","volume":"49","author":"J Domaradzki","year":"2015","unstructured":"Domaradzki J. The impact of Huntington disease on family carers: a literature overview. Psychiatr Pol. 2015;49(5):931\u201344.","journal-title":"Psychiatr Pol"},{"issue":"8","key":"2242_CR4","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/ene.15385","volume":"29","author":"H Furby","year":"2022","unstructured":"Furby H, Siadimas A, Rutten-Jacobs L, Rodrigues FB, Wild EJ. Natural history and burden of Huntington\u2019s disease in the UK: a population\u2010based cohort study. Eur J Neurol. 2022;29(8):2249\u201357.","journal-title":"Eur J Neurol"},{"issue":"4","key":"2242_CR5","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.rehab.2022.101703","volume":"66","author":"E Bayen","year":"2023","unstructured":"Bayen E, de Langavant LC, Youssov K, Bachoud-L\u00e9vi A-C. Informal care in Huntington\u2019s disease: assessment of objective-subjective burden and its associated risk and protective factors. Ann Phys Rehabil Med. 2023;66(4):101703.","journal-title":"Ann Phys Rehabil Med"},{"key":"2242_CR6","doi-asserted-by":"crossref","first-page":"117957352210925","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RL, Kwakowsky A. Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Disease. 2022;14:11795735221092517.","journal-title":"J Cent Nerv Syst Disease"},{"key":"2242_CR7","doi-asserted-by":"crossref","unstructured":"Drummond MF, Hartgers-Gubbels ES, Chambers M. Value Insider season 1 episode 1: the importance of payers and HTA: how did we end up here?(introduction to value)[podcast]. Int J Gen Med. 2022:7487\u201392.","DOI":"10.2147\/IJGM.S389025"},{"key":"2242_CR8","doi-asserted-by":"crossref","unstructured":"Rutten-van M\u00f6lken, Maureen PMH, Hartgers-Gubbels E, Sophia CM. Value Insider season 1 episode 4: how are costs measured, and how are CEAs constructed and used?(CEA)[podcast]. Int J Gen Med. 2022:8055\u201361.","DOI":"10.2147\/IJGM.S391712"},{"key":"2242_CR9","doi-asserted-by":"crossref","unstructured":"Devlin NJ, Hartgers-Gubbels ES, Chambers M. Value Insider season 1 episode 2: how to measure quality of life and utility?(QoL)[podcast]. Int J Gen Med. 2022:7773\u20139.","DOI":"10.2147\/IJGM.S390090"},{"key":"2242_CR10","unstructured":"van Lonkhuizen PJ, Frank W, Heemskerk A-W et al. Quality of life, health-related quality of life, and associated factors in Huntington\u2019s disease: a systematic review. J Neurol. 2023:1\u201322."},{"key":"2242_CR11","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"2242_CR12","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"2242_CR13","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s11136-015-0930-x","volume":"24","author":"NE Carlozzi","year":"2015","unstructured":"Carlozzi NE, Kratz AL, Downing NR, et al. Validity of the 12-item World Health Organization disability assessment schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Qual Life Res. 2015;24:1963\u201371.","journal-title":"Qual Life Res"},{"issue":"4","key":"2242_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1037\/pas0000479","volume":"30","author":"NE Carlozzi","year":"2018","unstructured":"Carlozzi NE, Hahn EA, Goodnight SM, et al. Patient-reported outcome measures in Huntington disease: quality of life in neurological disorders (Neuro-QoL) social functioning measures. Psychol Assess. 2018;30(4):450.","journal-title":"Psychol Assess"},{"issue":"4","key":"2242_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JHD-190364","volume":"8","author":"NE Carlozzi","year":"2019","unstructured":"Carlozzi NE, Goodnight S, Kratz AL, et al. Validation of Neuro-QoL and PROMIS mental health patient reported outcome measures in persons with Huntington disease. J Huntingtons Dis. 2019;8(4):467\u201382.","journal-title":"J Huntingtons Dis"},{"key":"2242_CR16","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s11136-016-1386-3","volume":"25","author":"NE Carlozzi","year":"2016","unstructured":"Carlozzi NE, Schilling S, Lai J-S, et al. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res. 2016;25:2441\u201355.","journal-title":"Qual Life Res"},{"issue":"4","key":"2242_CR17","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s12325-022-02046-z","volume":"39","author":"DO Claassen","year":"2022","unstructured":"Claassen DO, Ayyagari R, Goldschmidt D, Zhou M, Leo S, Ribalov R. Defining utility values for chorea health states in patients with Huntington\u2019s disease. Adv Ther. 2022;39(4):1784\u201393.","journal-title":"Adv Ther"},{"issue":"6","key":"2242_CR18","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1212\/CPJ.0000000000200095","volume":"12","author":"I Rodriguez Santana","year":"2022","unstructured":"Rodriguez Santana I, Frank S, Doherty M, et al. Humanistic burden of Huntington Disease: evidence from the Huntington disease burden of illness study. Neurol Clin Pract. 2022;12(6):e172\u201380.","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"2242_CR19","doi-asserted-by":"publisher","first-page":"27356","DOI":"10.3402\/jmahp.v4.27356","volume":"4","author":"J Dorey","year":"2016","unstructured":"Dorey J, Clay E, Khemiri A, Belhadj A, Cubillo PT, Toumi M. The quality of life of Spanish patients with Huntington\u2019s disease measured with H-QoL-I and EQ-5D. J Mark Access Health Policy. 2016;4(1):27356.","journal-title":"J Mark Access Health Policy"},{"key":"2242_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.parkreldis.2016.06.023","volume":"31","author":"L Quinn","year":"2016","unstructured":"Quinn L, Hamana K, Kelson M, et al. A randomized, controlled trial of a multi-modal exercise intervention in Huntington\u2019s disease. Parkinsonism Relat Disord. 2016;31:46\u201352.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2242_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/brainsci12020161","volume":"12","author":"A Exuzides","year":"2022","unstructured":"Exuzides A, Matos JE, Patel AM, Martin AA, Ricker B, Bega D. Understanding the burdens associated with Huntington\u2019s disease in manifest patients and care partners\u2013comparing to Parkinson\u2019s disease and the general population. Brain Sci. 2022;12(2):161.","journal-title":"Brain Sci"},{"key":"2242_CR22","doi-asserted-by":"crossref","unstructured":"Shaw E, Mayer M, Ekwaru P et al. Disease burden of Huntington\u2019s disease (HD) on people living with HD and care partners in Canada. J Huntingtons Dis. 2022(Preprint):1\u201315.","DOI":"10.3233\/JHD-210505"},{"key":"2242_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s10198-019-01092-9","volume":"20","author":"A Hawton","year":"2019","unstructured":"Hawton A, Green C, Goodwin E, Harrower T. Health state utility values (QALY weights) for Huntington\u2019s disease: an analysis of data from the European Huntington\u2019s disease network (EHDN). Eur J Health Econ. 2019;20:1335\u201347.","journal-title":"Eur J Health Econ"},{"key":"2242_CR24","doi-asserted-by":"crossref","unstructured":"Roos RAC. Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis. 2010;5(1):40.","DOI":"10.1186\/1750-1172-5-40"},{"key":"2242_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s11136-012-0269-5","volume":"22","author":"M Calvert","year":"2013","unstructured":"Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C. Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res. 2013;22:1231\u20138.","journal-title":"Qual Life Res"},{"issue":"2","key":"2242_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1399-0004.2011.01823.x","volume":"81","author":"M Hocaoglu","year":"2012","unstructured":"Hocaoglu M, Gaffan EA, Ho AK. The Huntington\u2019s Disease health-related quality of life questionnaire (HDQoL): a disease\u2010specific measure of health\u2010related quality of life. Clin Genet. 2012;81(2):117\u201322.","journal-title":"Clin Genet"},{"key":"2242_CR27","doi-asserted-by":"crossref","unstructured":"Carlozzi NE, Victorson D, Sung V, et al. HD-PRO-TRIAD\u2122 validation: A patient-reported instrument for the symptom triad of Huntington\u2019s Disease. Tremor Other Hyperkinet Mov (N Y). 2014;4.","DOI":"10.5334\/tohm.177"},{"key":"2242_CR28","doi-asserted-by":"crossref","unstructured":"Wild EJ, Tabrizi SJ, Wood N. Huntington\u2019s disease. Neurogenetics: A Guide for Clinicians Cambridge. Cambridge University Press; 2012. pp. 64\u201382.","DOI":"10.1017\/CBO9781139087711.006"},{"issue":"1","key":"2242_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-7-27","volume":"7","author":"D Rowen","year":"2009","unstructured":"Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7(1):1\u20139.","journal-title":"Health Qual Life Outcomes"},{"key":"2242_CR30","doi-asserted-by":"crossref","unstructured":"Billet J, Levine A, Johannesen J, et al. Patient experiences in early Huntington\u2019s disease-qualitative research to inform development of a patient-reported instrument of everyday functioning (P3-11.003). AAN Enterprises; 2022.","DOI":"10.1212\/WNL.98.18_supplement.2666"},{"key":"2242_CR31","unstructured":"Petrillo J, Sawant R, Lee A et al. Cognitive Performance and self-reported functioning in Huntington\u2019s disease: results from a real-world study. Presented at the CHDI Foundation 2023 Huntington\u2019s Disease Therapeutics Conference; 2023. Dubrovnik, Croatia."},{"issue":"4","key":"2242_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/JHD-180296","volume":"7","author":"K Watkins","year":"2018","unstructured":"Watkins K, Purks J, Kumar A, Sokas RK, Heller H, Anderson KE. Huntington\u2019s disease and employment: the relative contributions of cognitive and motor decline to the decision to leave work. J Huntington\u2019s Disease. 2018;7(4):367\u201377.","journal-title":"J Huntington\u2019s Disease"},{"issue":"6","key":"2242_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","volume":"19","author":"SE Wolowacz","year":"2016","unstructured":"Wolowacz SE, Briggs A, Belozeroff V, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19(6):704\u201319.","journal-title":"Value Health"},{"issue":"3","key":"2242_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3233\/JHD-170238","volume":"6","author":"NR Boileau","year":"2017","unstructured":"Boileau NR, Stout JC, Paulsen JS, et al. Reliability and validity of the HD-PRO-Triad TM, a health-related quality of life measure designed to assess the symptom triad of Huntington\u2019s disease. J Huntingtons Dis. 2017;6(3):201\u201315.","journal-title":"J Huntingtons Dis"},{"issue":"7","key":"2242_CR35","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s11136-021-03069-9","volume":"31","author":"AJ Geraerds","year":"2022","unstructured":"Geraerds AJ, Polinder S, Spronk I, et al. Sensitivity of the EQ-5D-5L for fatigue and cognitive problems and their added value in Q-fever patients. Qual Life Res. 2022;31(7):2083\u201392.","journal-title":"Qual Life Res"},{"issue":"4","key":"2242_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/0269215520907990","volume":"34","author":"JA de Graaf","year":"2020","unstructured":"de Graaf JA, Kuijpers MM, Visser-Meily JM, Kappelle LJ, Post MW. Validity of an enhanced EQ-5D-5L measure with an added cognitive dimension in patients with stroke. Clin Rehabil. 2020;34(4):545\u201350.","journal-title":"Clin Rehabil"},{"issue":"1","key":"2242_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12955-022-02036-3","volume":"20","author":"AD Keetharuth","year":"2022","unstructured":"Keetharuth AD, Hussain H, Rowen D, Wailoo A. Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review. Health Qual Life Outcomes. 2022;20(1):139.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2242_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-8-23","volume":"8","author":"C Mcgrath","year":"2010","unstructured":"Mcgrath C, Rofail D, Gargon E, Abetz L. Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer\u2019s disease. Health Qual Life Outcomes. 2010;8(1):1\u201313.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2242_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X20969686","volume":"41","author":"AP Finch","year":"2021","unstructured":"Finch AP, Brazier J, Mukuria C. Selecting bolt-on dimensions for the EQ-5D: testing the impact of hearing, sleep, cognition, energy, and relationships on preferences using pairwise choices. Med Decis Mak. 2021;41(1):89\u201399.","journal-title":"Med Decis Mak"},{"issue":"4","key":"2242_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0895-4356(98)00163-2","volume":"52","author":"PF Krabbe","year":"1999","unstructured":"Krabbe PF, Stouthard ME, Essink-Bot M-L, Bonsel GJ. The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. J Clin Epidemiol. 1999;52(4):293\u2013301.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2242_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jamiaopen\/ooy060","volume":"2","author":"Z Sun","year":"2019","unstructured":"Sun Z, Ghosh S, Li Y, et al. A probabilistic disease progression modeling approach and its application to integrated Huntington\u2019s disease observational data. JAMIA Open. 2019;2(1):123\u201330.","journal-title":"JAMIA Open"},{"key":"2242_CR42","unstructured":"Stimming EF. A Roadmap for HD - What comes next? 2015. http:\/\/hdsa.org\/wp-content\/uploads\/2015\/07\/HD-Roadmap2.pdf"},{"key":"2242_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40273-017-0546-9","volume":"35","author":"D Rowen","year":"2017","unstructured":"Rowen D, Brazier J, Ara R, Azzabi Zouraq I. The role of condition-specific preference-based measures in health technology assessment. PharmacoEconomics. 2017;35:33\u201341.","journal-title":"PharmacoEconomics"},{"key":"2242_CR44","unstructured":"Brazier J, Rowen D. NICE DSU Technical Support Document 11: alternatives to EQ-5D for generating health state utility values. 2011. Accessed 16 Mar 2017. http:\/\/www.nicedsu.org.uk"},{"key":"2242_CR45","unstructured":"Rowen D, Brazier J, Wong R, Wailoo A. Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available. Rep Decis Support Unit. 2020. https:\/\/www.sheffield.ac.uk\/nice-dsu\/methods-development\/measuring-health-related-quality-life"},{"key":"2242_CR46","doi-asserted-by":"crossref","unstructured":"Brazier J, Peasgood T, Mukuria C et al. The EQ health and wellbeing: overview of the development of a measure of health and wellbeing and key results. Value Health. 2022.","DOI":"10.1016\/j.jval.2022.01.009"},{"issue":"15 Supplement","key":"2242_CR47","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1212\/WNL.96.15_supplement.4360","volume":"96","author":"DO Claassen","year":"2021","unstructured":"Claassen DO, Goldschmidt D, Zhou M, Leo S, Ribalov R, Ayyagari R. Defining utility values for chorea health states in patients with Huntington\u2019s disease (4360). Neurology. 2021;96(15 Supplement):4360.","journal-title":"Neurology"},{"key":"2242_CR48","doi-asserted-by":"crossref","unstructured":"Rodriguez Santana I, Frank S, Fisher A, et al. POSB348 Differences in the health-related quality of life of Huntington\u2019s disease patients by disease stage in the US and EU5 from the Huntington\u2019s Disease Burden of Illness Study (HDBOI). Presented at the Value Health; 2022.","DOI":"10.1016\/j.jval.2021.11.1115"},{"issue":"12","key":"2242_CR49","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/MLR.0b013e31814848f1","volume":"45","author":"DG Fryback","year":"2007","unstructured":"Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care. 2007;45(12):1162.","journal-title":"Med Care"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02242-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-024-02242-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02242-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:16:06Z","timestamp":1713280566000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-024-02242-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1186\/s12955-024-02242-1","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jennifer Petrillo, Ruta Sawant, and Aaron Koenig are employees of Sage Therapeutics, Inc, and may hold stock. Kyle Paret, Sorrel Wolowacz, and Naoko Ronquest are employees of RTI Health Solutions. Dr. Hugh Rickards is an employee of the University of Birmingham. This study was conducted by RTI Health Solutions under the direction of Sage Therapeutics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}